Soligenix, Inc. SNGX stock is higher on Monday after the U.S. Food and Drug Administration granted orphan drug designation to dusquetide, the active ingredient in SGX945, for Behçet’s Disease.Follow SNGX stock’s rise today here.The update follows the review of recent Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behçet’s Disease.The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for rare diseases and disord ...